Skip to content
OpenCapital
Get started

10x Genomics, Inc. TXG Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value

Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value at other companies

BillionToOne, Inc. logo
BillionToOne, Inc. BLLN
——

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%—

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
10x Genomics, Inc. (TXG) reported share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value of $19.87 in Q1 2026.
How has 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value changed year-over-year?
10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value decreased by 29.9% year-over-year, from $28.35 to $19.87.
What is the long-term trend for 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value?
Over 5 years (2020 to 2025), 10x Genomics, Inc.'s share based compensation arrangement by share based payment award equity instruments other than options nonvested weighted average grant date fair value has grown at a -24.6% compound annual growth rate (CAGR), from $80.97 to $19.68.